
Direct-Acting Antivirals against Hepatitis C
Current Issues and Future Perspectives
- 1st Edition - February 1, 2026
- Editor: Mohamed Mahmoud Zakaria El-Kassas
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 4 1 3 6 3 - 6
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 4 1 3 6 4 - 3
Direct-Acting Antivirals against Hepatitis C: Current Issues and Future Perspectives is a comprehensive reference that explores Chronic Hepatitis C management. This author… Read more

Direct-Acting Antivirals against Hepatitis C: Current Issues and Future Perspectives is a comprehensive and indispensable resource for anyone involved in the management of Chronic Hepatitis C. With its in-depth exploration of DAAs, from their molecular mechanisms to their clinical applications and future directions, this book equips clinicians, researchers, and students with the knowledge and insights needed to enhance their practices and contribute to the global fight against HCV infection.
- Provides the latest scientific analyses and discussions on Direct-Acting Antivirals (DAAs) for hepatitis C virus (HCV) treatment to explain the molecular mechanisms, therapeutic effectiveness, and advancements in CHC management
- Includes insights from leading experts in hepatology, virology, pharmacology, and immunology for comprehensive view of current HCV research and therapy, emerging strategies, and technologies
- Shares strategic insights to optimize DAA therapy to overcome challenges like resistance development, managing specific patient populations, and combining DAAs with other treatments
1. Hepatitis C Virus Overview
2. HCV-Host Interactions: Virus specific factors, virus host related determinants, and Intracellular Signaling
3. Introduction to Direct-Acting Antivirals: Mechanisms of Action and different classes
Section 2. Therapeutic Strategies and Clinical Applications of DAAs in managing HCV
4. Clinical Efficacy of different DAAs regimens
5. Safety and tolerability of different DAAs regimens
6. Benefits of treating HCV by DAAs beyond virological response
7. Current landscape and guidelines of DAAs treatment in general population
8. Individualized treatment approaches in various special patient populations
Section 3. Challenges and Future Directions in DAA Therapy
9. Antiviral Resistance in Hepatitis C and DAA Therapy
10. DAA Therapy and hepatocellular carcinoma
11. Limitations and unmet needs in DAAs therapy
12. Emerging Therapeutic Strategies and Future Directions
13. Access to DAAs therapy, and role of DAAs in targeted HCV elimination
- Edition: 1
- Published: February 1, 2026
- Language: English
ME
Mohamed Mahmoud Zakaria El-Kassas
Mohamed El-Kassas, a distinguished figure in hepatology, held prestigious positions in global medical organizations such as IASL, AHPBCC, WGO, Global NASH Council, and SLMENA. He has also held administrative roles in EARTH and the Egyptian National Committee for the Control of Viral Hepatitis. With a PG Diploma in Clinical Research, he received awards and recognition for his research, including the Best Arab Researcher Prize in Natural Sciences. He has published over 200 peer-reviewed manuscripts and served on the editorial boards of journals like PLOS One, Frontiers, and JCTH. He also reviewed for over 70 international journals, contributing to the field of hepatology.